Abhibol Inobhas1,2, Sunee Chansangpetch1,2,3, Anita Manassakorn1,2,3, Visanee Tantisevi1,2,3, Prin Rojanapongpun1,2,3. 1. Department of Ophthalmology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. 2. King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand. 3. Glaucoma Research Unit, Chulalongkorn University, Bangkok, Thailand.
Abstract
PURPOSE: The effect of statins on wound healing is controversial, and their effect on trabeculectomy outcomes remains unclear. This study aimed to examine the relationship between oral statin use and trabeculectomy outcomes. METHODS: Medical records of patients who underwent primary mitomycin-C augmented trabeculectomy with 2 years of follow-up were reviewed. Pre- and postoperative intraocular pressures (IOP) and numbers of medications, subconjunctival 5-fluorouracil (5-FU) injections, and bleb-needling procedures were compared between statin users and nonusers. Failure was defined as an eye that failed to achieve a 20% lowering of IOP from baseline or had an IOP > 21 mm Hg, as well as an eye that required further surgical intervention, developed hypotony, or had no light perception visual acuity. RESULTS: In total, 158 subjects were enrolled, with 47 eyes from statin users and 111 eyes from statin nonusers. The 24-month cumulative probability of failure was 78.7% for statin users and 60.4% for nonusers (P = .013). Cox proportional-hazards modeling showed a significantly higher hazard risk in statin users (adjusted hazard ratio 1.61, P = .026). There were no significant between-group differences in mean IOPs or number of medications (both P > .05) at 24 months. Multivariable Poisson regression analysis that statin use was associated with increased numbers of 5-FU injections (P = .014) and bleb-needling procedures (P = .031). CONCLUSIONS: This study demonstrated that oral statin use was associated with higher rates of trabeculectomy failure and increased numbers of 5-FU injections and bleb-needling procedures.
PURPOSE: The effect of statins on wound healing is controversial, and their effect on trabeculectomy outcomes remains unclear. This study aimed to examine the relationship between oral statin use and trabeculectomy outcomes. METHODS: Medical records of patients who underwent primary mitomycin-C augmented trabeculectomy with 2 years of follow-up were reviewed. Pre- and postoperative intraocular pressures (IOP) and numbers of medications, subconjunctival 5-fluorouracil (5-FU) injections, and bleb-needling procedures were compared between statin users and nonusers. Failure was defined as an eye that failed to achieve a 20% lowering of IOP from baseline or had an IOP > 21 mm Hg, as well as an eye that required further surgical intervention, developed hypotony, or had no light perception visual acuity. RESULTS: In total, 158 subjects were enrolled, with 47 eyes from statin users and 111 eyes from statin nonusers. The 24-month cumulative probability of failure was 78.7% for statin users and 60.4% for nonusers (P = .013). Cox proportional-hazards modeling showed a significantly higher hazard risk in statin users (adjusted hazard ratio 1.61, P = .026). There were no significant between-group differences in mean IOPs or number of medications (both P > .05) at 24 months. Multivariable Poisson regression analysis that statin use was associated with increased numbers of 5-FU injections (P = .014) and bleb-needling procedures (P = .031). CONCLUSIONS: This study demonstrated that oral statin use was associated with higher rates of trabeculectomy failure and increased numbers of 5-FU injections and bleb-needling procedures.
Authors: Jae H Kang; Tahani Boumenna; Joshua D Stein; Anthony Khawaja; Bernard A Rosner; Janey L Wiggs; Louis R Pasquale Journal: JAMA Ophthalmol Date: 2019-07-01 Impact factor: 7.389
Authors: Julia Song; Pei-Feng Deng; Sandra S Stinnett; David L Epstein; P Vasantha Rao Journal: Invest Ophthalmol Vis Sci Date: 2005-07 Impact factor: 4.799
Authors: Steven J Gedde; Joyce C Schiffman; William J Feuer; Leon W Herndon; James D Brandt; Donald L Budenz Journal: Am J Ophthalmol Date: 2009-08-11 Impact factor: 5.258